IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#4018
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$26M
Erez Aminov
We are an early pre-clinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic THC analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. Our corporate headquarters is located at 855 N Wolfe Street, Suite 601, Baltimore, Maryland.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MIRA MIRA PHARMACEUTICALS, INC. | 36 | 23 | 32 | 44 | - | - | -86.1% | -85.2% | - | - | - | - | 0.0% | 1.0x | $26M | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
MIRA PHARMACEUTICALS, INC. (MIRA) receives a "Avoid" rating with a composite score of 35.9/100. It ranks #4018 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
In-line with peers — no strong momentum signal
Expensive relative to fundamentals — limited margin of safety
Weak fundamentals — higher risk of value trap
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for MIRA.
View All RatingsROE proxy -86.1% (sector -1.9%)
GM N/A vs sector 44%, OM N/A vs sector 3%
Capital turnover N/A
Rev growth N/A
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate MIRA PHARMACEUTICALS, INC. (MIRA) as Avoid with a composite score of 35.9/100 at a current price of $1.25. The stock falls in the bottom quintile, and the multi-factor weakness suggests a high probability of continued underperformance.
MIRA PHARMACEUTICALS, INC. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 35.9/100 places it at rank #4018 in our full universe.
No Moat
Low
Poor
Fair Value
Stable competitive position in a defensive sector.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
MIRA PHARMACEUTICALS, INC. represents a avoid based on multi-factor quantitative performance.
Our quantitative model flags MIRA PHARMACEUTICALS, INC. with an Avoid rating, assigning a composite score of 35.9/100 and 1 out of 5 stars. Ranked #4018 of 7,333 stocks, MIRA falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
MIRA PHARMACEUTICALS, INC. registers a weak quality score of just 23/100, indicating significant profitability challenges. The company reports a return on equity of -86.1% (sector avg: -1.9%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.
With a value score of 32/100, MIRA appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 6.60x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
MIRA PHARMACEUTICALS, INC.'s investment score of 35/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -85.2% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
MIRA is currently showing below-average momentum at 44/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 0.55 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
With a stability score of 55/100, MIRA exhibits average financial resilience. Key stability metrics include a beta of 0.55 and a debt-to-equity ratio of 1.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
The short interest score of 41/100 for MIRA suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include micro-cap liquidity risk. With a $26M market cap (micro-cap), MIRA PHARMACEUTICALS, INC. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
MIRA PHARMACEUTICALS, INC. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4018 of 7,333 overall (45th percentile). Key comparisons include ROE of -86.1% trailing the -1.9% sector median. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While MIRA currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Quality (23) would have the largest impact on the composite score.
ROE 4434% ABOVE SECTOR MEDIAN (FAVORABLE)
Debt/Equity 376% ABOVE SECTOR MEDIAN
Div. Yield NaN% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
MIRA Pharmaceuticals' board has approved the acquisition of SKNY Pharmaceuticals, a move that creates a combined entity valued at over $60 million. This acquisition is a significant strategic step for MIRA, expanding its pharmaceutical portfolio and market presence.
MIRA Pharmaceuticals (NASDAQ:MIRA) announced favorable topline results from the Phase 1 single ascending dose (SAD) study of its oral therapeutic Ketamir-2. The study demonstrated that Ketamir-2 was safe and well-tolerated across all dose levels, exhibiting predictable pharmacokinetics and no central nervous system side effects typically associated with ketamine. These findings support once-daily dosing for conditions like neuropathic pain and position Ketamir-2 as a promising non-scheduled drug candidate.
Mira Pharmaceuticals (NASDAQ:MIRA) has announced the approval of incentive awards for CEO Erez Aminov, including a short-term incentive, a contingent payout for a clinical study, and a significant bonus for the SKNY Pharmaceutical acquisition. He also received performance share units for achieving a market capitalization milestone. This comes amidst other developments like an increased at-the-market offering and advancements in clinical trials for Ketamir-2 and Mira-55.
MIRA Pharmaceuticals has initiated the multiple ascending dose (MAD) portion of its Phase 1 clinical trial for oral Ketamir-2 in healthy volunteers and selected chemotherapy-induced peripheral neuropathy (CIPN) as the lead indication for its upcoming Phase 2a study. Preclinical data for Ketamir-2 has shown promising results in treating neuropathic pain, outperforming established medications like ketamine, gabapentin, and pregabalin in animal models. The company aims to address a significant unmet medical need in CIPN, a condition without FDA-approved treatments, positioning Ketamir-2 as a potential non-opioid therapeutic option.
Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer Research (AACR)Annual Meeting MIAMI, FLORIDA / ACCESS Newswire / February 3, 2026 /MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" ...